Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MCR161
MIFTS: 23

Macroglobulinemia, Waldenstrom 1

Categories: Rare diseases, Neuronal diseases, Blood diseases, Immune diseases
Genes Tissues Related diseases Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Macroglobulinemia, Waldenstrom 1

About this section

MalaCards integrated aliases for Macroglobulinemia, Waldenstrom 1:

Name: Macroglobulinemia, Waldenstrom 1 57
Macroglobulinemia, Waldenstrom, Susceptibility to, 1 57 13
Wm1 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
macroglobulinemia, waldenstrom 1:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Macroglobulinemia, Waldenstrom 1

About this section
OMIM : 57 Waldenstrom macroglobulinemia (WM) is a malignant B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and hypersecretion of monoclonal immunoglobulin M (IgM) protein (review by Vijay and Gertz, 2007). The importance of genetic factors is suggested by the observation of familial clustering of WM (McMaster, 2003). Whereas WM is rare, an asymptomatic elevation of monoclonal IgM protein, termed 'IgM monoclonal gammopathy of undetermined significance' (IgM MGUS) is more common. Patients with IgM MGUS can progress to develop WM, at the rate of 1.5% to 2% per year (Kyle et al., 2003). (153600)

MalaCards based summary : Macroglobulinemia, Waldenstrom 1, also known as macroglobulinemia, waldenstrom, susceptibility to, 1, is related to waldenstrom macroglobulinemia. An important gene associated with Macroglobulinemia, Waldenstrom 1 is WM1 (Macroglobulinemia, Waldenstrom, Susceptibility To, 1). The drugs Chlorambucil and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are polyneuropathy and leukemia

Sources

Related Diseases for Macroglobulinemia, Waldenstrom 1

About this section

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 1 Macroglobulinemia, Waldenstrom 2

Diseases related to Macroglobulinemia, Waldenstrom 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 waldenstrom macroglobulinemia 10.9

Sources

Symptoms & Phenotypes for Macroglobulinemia, Waldenstrom 1

About this section

Symptoms via clinical synopsis from OMIM:

57
Heme:
waldenstrom macroglobulinemia

Neuro:
polyneuropathy

Oncology:
increased frequency of lymphoma, leukemia, and adenocarcinom of lung

Lab:
impaired lymphocyte transformation with phytohemagglutinin
polyclonal elevation of igm


Clinical features from OMIM:

153600

Human phenotypes related to Macroglobulinemia, Waldenstrom 1:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 polyneuropathy 32 HP:0001271
2 leukemia 32 occasional (7.5%) HP:0001909
3 lymphoma 32 occasional (7.5%) HP:0002665
4 impaired lymphocyte transformation with phytohemagglutinin 32 HP:0003347
5 polyclonal elevation of igm 32 HP:0003459
6 monoclonal immunoglobulin m proteinemia 32 HP:0005508
Sources

Drugs & Therapeutics for Macroglobulinemia, Waldenstrom 1

About this section

Drugs for Macroglobulinemia, Waldenstrom 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 3 305-03-3 2708
2
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
3
Vidarabine Approved, Investigational Phase 3 24356-66-9 32326 21704
4 Alkylating Agents Phase 3
5 Anti-Infective Agents Phase 3
6 Antimetabolites Phase 3
7 Antimetabolites, Antineoplastic Phase 3
8 Antineoplastic Agents, Alkylating Phase 3
9 Antiviral Agents Phase 3
10 Immunosuppressive Agents Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
2 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate

Search NIH Clinical Center for Macroglobulinemia, Waldenstrom 1

Sources

Genetic Tests for Macroglobulinemia, Waldenstrom 1

About this section
Sources

Anatomical Context for Macroglobulinemia, Waldenstrom 1

About this section

MalaCards organs/tissues related to Macroglobulinemia, Waldenstrom 1:

41
B Cells, Bone, Bone Marrow, Lung
Sources

Publications for Macroglobulinemia, Waldenstrom 1

About this section
Sources

Variations for Macroglobulinemia, Waldenstrom 1

About this section
Sources

Expression for Macroglobulinemia, Waldenstrom 1

About this section
Search GEO for disease gene expression data for Macroglobulinemia, Waldenstrom 1.
Sources

Pathways for Macroglobulinemia, Waldenstrom 1

About this section
Sources

GO Terms for Macroglobulinemia, Waldenstrom 1

About this section
Sources

Sources for Macroglobulinemia, Waldenstrom 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....